CSB-001 Ophthalmic Solution 0.1%

BIOLOGICAL3 trials

Sponsors

Claris Biotherapeutics, Inc.

Conditions

Corneal ScarLimbal Stem Cell DeficiencyNeurotrophic Keratitis

Phase 1

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

CompletedNCT04909450

Claris Biotherapeutics, Inc.Neurotrophic Keratitis

Start: 2021-08-24End: 2024-06-04Updated: 2026-05-13

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

RecruitingNCT06257355

Claris Biotherapeutics, Inc.Corneal Scar

Start: 2024-02-05End: 2027-06-30Target: 20Updated: 2026-04-07

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Limbal Stem Cell Deficiency

RecruitingNCT06452316

Claris Biotherapeutics, Inc.Limbal Stem Cell Deficiency

Start: 2024-05-15End: 2027-12-31Target: 75Updated: 2026-08-13